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Interestingly, the amount of cytoplasmic dynein intermediate chain 1(DIC1) was also increased as we previously reported in mice 7 . LIS1 is required for plus-end directed transport of cytoplasmic dynein 6 . When LIS1 is mutated, the centrosomal accumulation of LIS1 is reduced, resulting in the impairment of plus-end directed transport of cytoplasmic dynein. As a result, cytoplasmic dynein is abnormally accumulated around the centrosome 6 . Therefore, we determined whether SNJ1945 rescued the distribution of Cerebellar granule cells were isolated as described previously, and cultured at 10 6 cells/ml for 12 hrs, resulting in uniform-sized reaggregates (100-150 µm in diameter), which were then transferred to poly-L-lysine-(Sigma-Aldrich) and laminin (Sigma-Aldrich)-treated slides and incubated for 8 hrs. Then, 200 µM SNJ1945 or control DMSO was added and the cultures were further incubated for 16 h. Imaging was commenced using a 20x objective lens and images were analyzed using a confocal microscope (TCS-SP5, Leica).
Supplementary Figure 4 No toxic effect of high doses of SNJ1945 on granular neurons.
Calpain inhibitors act as a potent inhibitor of thiol proteases, which protect proteolysis from cystein proteases including calpainI, calpainII, cathepsinB and cathepsinL. Lack of selectivity of calpain inhibitors causes adverse effects, which limits their therapeutic use.
To address neurotoxic effects of calpain inhibitors, we administrated doses five times greater than effective concentration of each calpain inhibitor. The treatment with 50 µM of ALLN (c) or 100 µM of E64d (d) displayed obvious neurotoxic effects, which was characterized by deformity of cell body and lack of cell aggregate of granular neurons.
In contrast, the treatment of 1 mM SNJ1945 displayed no obvious adverse effects (b),
suggesting that SNJ1945 has no obvious toxicity on neurons. from E9.5 clearly recovered architecture of the hippocampus. In contrast, structural improvement of the hippocampus was limited to oral administration of SNJ1945 from peri-natal stage (c).
Supplementary Figure 7 Behavior analysis
Rotarod test. The latency to fall in each trial was shown.
Supplementary Figure 8 Quantification of 18 F-FDG uptake
Quantification of 18 F-FDG uptake in several brain regions of each experimental group (Lis1 +/+ ; Lis1 +/+ mice without treatment (n=8), Lis1 +/-; Lis1 +/mice without treatment (n=8), Lis1 +/-E9.5; Lis1 +/mice with SNJ1945 treatment from E9.5 (n=6), Lis1 +/-P0;
Lis1 +/mice with SNJ1945 treatment from peri-natal period (n=7) Lis1 +/-P10; Lis1 +/mice with SNJ1945 treatment from ten days after birth (n=6)). Data are shown as mean ± SEM. Measured area of brain was indicated at the top of each graph. There was no significant difference in the frequency of anterograde transport of Qd-NGF containing endosomes.
Supplementary

Supplementary table 1 Determination of the concentration of SNJ1945 in the brain using LC-MS/MS
The SNJ1945 concentration in the brain was determined by turbo ion spray on an API 4000 triple-quadrupole mass spectrometer (LC-MS/MS). Warfarin was used as internal standard (IS). Various concentrations of SNJ1945 (0.1 ng/mL-10,000 ng/mL) were mixed IS and were subjected to LC-MS/MS analysis (upper panel). The standard curve was linear from 100-10,000 ng/mL by the comparison with warfarin peak area. The
